Novo Nordisk

        2024.12.23
    
22:33

                            Novo Nordisk rebounded by more than 4%
                        
                            Novo Nordisk rebounded more than 4%, as analysts said the company's weight loss drugs are still the most effective.
                        
16:08

                            Novo Nordisk's European shares rose 6.2%, on track for their best performance since August.
                        
16:04

                            Novo Nordisk shares opened up 6% in Europe
                        
                            Novo Nordisk's European shares opened 6% higher.
                        
        2024.12.20
    
22:33

                            Eli Lilly (LLY.N) rose more than 4% as rival Novo Nordisk's weight loss drug trial results fell short of expectations.
                        
19:33

                            Novo Nordisk spokesperson: The Cagrisema trial allowed for dose reduction; even though only 57% of Cagrisema patients reached the highest dose, statistically significant results were achieved.
                        
19:32

                            Novo Nordisk spokesperson: Regulatory filing for Cagrisema is expected by the end of 2025. We are encouraged by the properties of Cagrisema, which appears safe, well tolerated, and broadly similar to other GLP-1s.
                        
19:32

                            Novo Nordisk spokesperson: We plan to optimize dose adjustments and further explore Cagrisem's potential for additional weight loss, with plans to start a new trial in the first half of 2025.
                        
19:31

                            Novo Nordisk spokesperson: The complete Cagrisema results will be announced at a medical congress next year.
                        
19:12

                            Novo Nordisk's pre-market decline in US stocks narrowed to 20%, while Eli Lilly rose more than 10%
                        
                            Novo Nordisk's pre-market decline narrowed to 20%, after a sharp drop of nearly 30%, the largest single-day drop on record, due to the company's weight loss drug CagriSema trial results falling short of expectations. Eli Lilly's pre-market rise was more than 10%.
                        
19:04

                            Novo Nordisk shares plunge 27%, dragging down Stoxx Europe 600 2%
                        
                            The Stoxx Europe 600 index fell 2% to 496.52 points. Novo Nordisk shares plunged 27%, the biggest one-day drop in 22 years, as the results of the Novo Nordisk weight loss drug CagriSema trial fell short of expectations. Novo Nordisk said on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, lower than its expected 25%, causing its shares to fall sharply.
                        
19:01

                            Novo Nordisk shares plunged 23%, their biggest one-day drop in 22 years, after the company's weight-loss drug CagriSema trial results fell short of expectations.
                        
18:55

                            The Euro Stoxx Healthcare index fell 4.4%, its biggest one-day drop since March 2020, hit by the results of Novo Nordisk's weight loss drug trial.
                        
18:53

                            Novo Nordisk fell more than 19 percent in premarket trading after the company reported weaker-than-expected data for its weight-loss drug Cagrisema, while Eli Lilly (LLY.N) rose nearly 6 percent in premarket trading.
                        
18:49

                            Novo Nordisk's stock price fell more than 17% in pre-market trading in the US
                        
                            Novo Nordisk's stock price fell more than 17% in pre-market trading in the U.S. after the release of the Cagrisema data.
                        
        2024.12.16
    
14:34

                            Novo Nordisk: Investing DKK 8.5 billion to build a new production facility in Odense, Denmark, which will create 400 permanent jobs. Construction of the project has begun and is expected to be completed in 2027. The new base will have state-of-the-art finished product production facilities and a warehouse covering more than 40,000 square meters.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Taiwan's weighted index rose 2.6%, with semiconductor stocks leading the gains, and TSMC rising more than 4%
                            2024-12-23

                                    Huawei's Automotive BU spin-off is in the countdown, and old employees are expected to receive extra compensation when they transfer to other companies? Insider: I haven't heard of it.
                            2024-12-27

                                    Tuanmaimai, the WeChat community group buying business under Meituan (03690.HK), issued an announcement stating that due to platform business adjustments, Tuanmaimai will cease operations from 24:00 on December 31, 2024.
                            2024-12-23

                                    Mao Yinian, Vice President of Meituan: Meituan has invested in several robot companies including Yushu and Galaxy General
                            2024-12-27

                                    A-share SMIC rose more than 5%
                            2024-12-27